ArticleFrontiers in medicine2026
Tinea barbae following ruxolitinib cream application in a vitiligo patient: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ruxolitinib 1.5% cream, a topical Janus Kinase (JAK) 1/2 inhibitor, represents a novel targeted treatment for non-segmental vitiligo, a common acquired depigmentation disorder of autoimmune origin clinically characterized by milky-white patches on the affected body areas. The efficacy of topical ruxolitinib in vitiligo has been demonstrated in clinical trials and real-life observation, with an overall safety profile. Mild-to-moderate reported adverse events include site-application acne, nasopharyngitis, and site-application pruritus, while increased susceptibility to viral skin infections, due to its mechanism of action leading to local immunosuppression, remains debated. No data are currently available on the potential susceptibility to fungal infection. We present here a case of a 53-year-old man who developed tinea barbae by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.